Program

The Best of ASCO Program presents the scientific and educational highlights of the ASCO Annual Meeting selected from the year’s notable abstracts. Please see the agenda for more information.

Meeting Chair: David R. Spigel, MD, Sarah Cannon Research Institute

7:00 AM–3:10 PM Exhibits Open

7:00 AM–7:55 AM

Registration and Continental Breakfast

7:55 AM–8:00 AM

Welcome and Chair Remarks

 

David R. Spigel, MD

Sarah Cannon Research Institute

8:00 AM–8:40 AM

Gastrointestinal (Colorectal) Cancer

 

Kimmie Ng, MD, MPH

Dana-Farber Cancer Institute


Abstract LBA1Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration(Qian Shi)
Abstract 3503Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)(Alan Venook)
Abstract 3505Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). (Scott Kopetz)
Abstract 3507Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (Ricky Sharma)

8:40 AM–9:20 AM

Gastrointestinal (Non-colorectal) Cancer

 

Manish Shah, MD

New York Presbyterian Hospital and Weill Cornell Medical Center


Abstract 4001Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)(Ann-Lii Cheng)
Abstract 4006Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. (John Primrose)
Abstract 4007Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma(Howard Safran)
Abstract 4014Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (Yelena Janjigian)

9:20 AM–9:40 AM

Panel Question and Answer: Gastrointestinal Cancers

 

Kimmie Ng, MD, MPH

Dana-Farber Cancer Institute

 

Manish Shah, MD

New York Presbyterian Hospital and Weill Cornell Medical Center

9:40 AM–10:00 AM

Break

10:00 AM–10:40 AM

Breast Cancer—Local/Regional/Adjuvant

 

Nancy U. Lin, MD

Dana-Farber Cancer Institute


Abstract LBA500APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). (Gunter Von Minckwitz)
Abstract 504Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Nadia Harbeck)
Abstract 506Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. (Rita Nanda)
Abstract 508Mastectomy rates in relation to adoption of a margin guideline. (Monica Morrow)

10:40 AM–11:20 AM

Breast Cancer—Metastatic

 

Ruth O'Regan, MD

University of Wisconsin


Abstract LBA4OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). (Mark Robson)
Abstract 1000MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (George Sledge)
Abstract 1001Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). (Richard Finn)
Abstract 1008Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (Sylvia Adams)

11:20 AM–11:40 AM

Panel Question and Answer: Breast Cancers

 

Nancy U. Lin, MD

Dana-Farber Cancer Institute

 

Ruth O'Regan, MD

University of Wisconsin

11:40 AM- 12:30 PM Complimentary Boxed Lunch

11:50 AM–12:20 PM

Meet the Professfor Roundtables

For more information, visit Onsite Networking

12:30 PM–1:10 PM

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

 

Daniel DeAngelo, MD, PhD

Dana-Farber Cancer Institute


Abstract 7000Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF). (Ruben Mesa)
Abstract 7002Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. (Jorge Cortes)
Abstract 7004Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study. (Eytan Stein)
Abstract 7006Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial. (Richard Ambinder)

1:10 PM–1:50 PM

Hematologic Malignancies—Plasma Cell Dyscrasia

 

Brea Lipe, MD

University of Rochester


Abstract 8000Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. (Andrzej Jakubowiak)
Abstract 8003Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). (Francesca Maria Gay)
Abstract 8005Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. (Noopur Raje)

1:50 PM–2:30 PM

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

 

John Pagel, MD, PhD

Swedish Cancer Institute


Abstract 7500First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. (Ian Flinn)
Abstract 7503A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). (Amy Ruppert)
Abstract 7506Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.(Michael Pfreundschuh)
Abstract 7508Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Bone Marrow Transplant Research (CIBMTR) analysis. (James Godfrey)

2:30 PM–2:50 PM

Panel Question and Answers: Hematologic Malignancies

 

Daniel DeAngelo, MD, PhD

Dana-Farber Cancer Institute

 

Brea Lipe, MD

University of Rochester

 

John Pagel, MD, PhD

Swedish Cancer Institute

2:50 PM–3:10 PM Break
3:10 PM–4:30 PM

Town Hall: Practice Realities in a Shifting Policy Landscape

 

Elizabeth Blanchard, MD

Southcoast Centers for Cancer Care

 

Therese Mulvey, MD, FASCO

Massachusetts General Hospital Cancer Center

 

Blase Polite, MD

University of Chicago

 

Robin Zon, MD, FACP, FASCO

Michiana Hematology Oncology